The experiment on labeling certain medicinal products for human use with control (identification) marks and monitor their circulation is conducted in the Russian Federation from February 1 to December 31, 2017.
During the experiment, the manufacturers are using 2D bar code to label the medicinal products with control (identification) marks. The application of this labeling does not require any changes to the registration dossier of the medicinal product.
As of June 1, 2017, the following manufacturers of medicinal products are participating in the experiment: Astellas Ireland Co. Ltd.; Pfizer Manufacturing Deutchland GmbH; Aktavis Italy SpA; Research Institute for Chemical Diversity JSC; BioIntegrator LLC; Niarmedic LLC; ORTAT JSC; GEROPHARM LLC; Sintez JSC; BIOCAD CJSC; NPO Petrovax Pharm LLC; Pharmstandard – Ufa Vitamin Plant JSC; Dobrolek LLC; Astra Zeneca Industries LLC; Hemofarm LLC; Nizhpharm JSC; Gedeon Richter Rus JSC; FSUE NPO Microgen of the Ministry of Health of Russia; Serdix LLC; Takeda Pharmaceuticals LLC; Nativa LLC; Amgen Europe BV; Hoffmann-La Roche Ltd.; Pharmaceutical Company LEK d.d.; Krka, d. d., Novo mesto; Boehringer Ingelheim Pharma GmbH & Co. KG; Bayer Weimar GmbH & Co.; Novartis Pharma Stein AG; Dr. Reddy’s Laboratories Ltd.; Gedeon Richter-Hungary; Johnson & Johnson; Bosnalek Pharmaceutical Company; Nobel Ilac Sanayi ve Ticaret Anonim Sirketi; Canonpharma CJSC; Abbott Laboratories LLC.